HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases.

AbstractBACKGROUND:
Optimal chemotherapeutic regimen in thymic carcinoma remains uncertain and the efficacy of second line chemotherapy has not been established either.
PATIENTS AND METHODS:
We retrospectively evaluated the efficacy of an irinotecan plus cisplatin or carboplatin (IP) regimen as a salvage treatment for patients with unresectable thymic carcinoma that progressed after cisplatin, doxorubicin, vincristine and cyclophosphamide (ADOC) chemotherapy. Seven patients with histologically confirmed thymic carcinoma that was resistant to or who had relapsed after initial chemotherapy with ADOC were treated with IP. The treatment consisted of irinotecan (CPT-11, 60 mg/m2, days 1, 8 and 15) and cisplatin (80 mg/m2, day 1) or carboplatin (AUC 4) intravenously every 4 weeks, for at least 2 cycles.
RESULT:
Two patients achieved partial responses. Although another two patients showed a significant reduction of the primary thoracic lesion, the appearance of a new lesion was found in one and a metastatic lesion was unchanged in the other. Neutropenia over grade 3 was observed in all patients but none of the patients developed serious infections. There were no severe non-hematological toxicities, including diarrhea.
CONCLUSION:
We conclude that salvage chemotherapy may be useful in certain patients with thymic carcinoma and irinotecan may be a novel and alternative agent for relapsed thymic carcinoma.
AuthorsShintaro Kanda, Tomonobu Koizumi, Yoshimichi Komatsu, Sumiko Yoshikawa, Mitsuyo Okada, Orie Hatayama, Masanori Yasuo, Kenji Tsushima, Kazuhisa Urushihata, Keishi Kubo, Mari Sasabayashi, Akemi Takamizawa
JournalAnticancer research (Anticancer Res) 2007 Jul-Aug Vol. 27 Issue 4C Pg. 3005-8 ISSN: 0250-7005 [Print] Greece
PMID17695487 (Publication Type: Journal Article)
Chemical References
  • Vincristine
  • Irinotecan
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin
  • Cisplatin
  • Camptothecin
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Camptothecin (adverse effects, analogs & derivatives)
  • Carboplatin (administration & dosage)
  • Cisplatin (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Female
  • Humans
  • Irinotecan
  • Male
  • Middle Aged
  • Retrospective Studies
  • Survival Rate
  • Thymus Neoplasms (drug therapy)
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: